Effects of CD40 stimulation in the prevention of human EBV-lymphomagenesis

Leukemia and Lymphoma

Volumn 24, Issue 3-4, 1997, Pages 187-199

  Funakoshi, Satoshi ^a   Taub, Dennis D ^b   Asai, Osamu ^b   Hirano, Akio ^b   Ruscetti, Francis W ^b   Longo, Dan L ^c   Murphy, William J ^d  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTE ON AGING   (United States)

^d SAIC FREDERICK INC   (United States)

Author keywords

B cell; CD40; Epstein Barr virus; Human mouse chimera; Immunotherapy; Lymphoma

Indexed keywords

CD40 ANTIGEN; GLYCOPROTEIN GP 39;

B CELL LYMPHOMA; B LYMPHOCYTE DIFFERENTIATION; CELL GROWTH; CELL STIMULATION; CHIMERA; EPSTEIN BARR VIRUS; HISTOLOGY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; VIRUS CARCINOGENESIS;

EID: 0031040494     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428199709039007     Document Type: Review

References (32)

1. Henle, W V., Diehe, G., Kohn, H., Zur Hausen, H. and Hughs- Jones, H (1967). Herpes-type virus and chromosome marker in normal leukocyte after growth with irradiated Burkitt's cells, Science, 157, 1064.
2. Straus, S. E., Cohen, J. I., Tosato, G. and Meier, J. (1993). Epstein-Barr virus infections: biology, pathogenesis, and management, Ann. Intern. Med., 118, 45.
3. Mosier, D. E., Gulizia, R. J., Baird, S. M. and Wilson, D. B. (1988). Transfer of a functional human immune system to mice with severe combined immunodeficiency, Nature, 335, 256.
4. Murphy, W. J., Funakoshi, S., Beckwith, M., Rushing, S. E., Conley, D K., Armitage, R. J., Fanslow, W. C. Rager, H. C., Taub, D. D., Ruscetti, F. W. and Longo, D. L. (1995). Antibodies to CD40 prevent Epstein-Barr virus-mediated human B-cell lymphomagenesis in severe combined immune deficient mice given human peripheral blood lymphocytes, Blood, 86, 1946.
5. Armitage, R. J., Maliszewski, C. R., Alserson, M. R., Grabstein, K. H., Spriggs, M. K. and Fanslow, W. C. (1993). CD40L: A multi-functional ligand. Semin. Immunol., 5, 401.
6. Ledbetter, J. A., Shu, G., Gallagher, M. and Clark, E. A. (1987). Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40), J. Immunol. 138, 788.
7. Nonoyama, S., Hollenbaugh, D., Aruffo, A., Ledbetter, J. A. and Ochs, H. D. (1993). B cell activation via CD40 is required for specific antibody production by antigen-stimulated human B cells, J Exp. Med., 178, 1097.
8. Splawski, J. B., Fu, S. M. and Lipsky, P. E. (1993). Immunoregulatory role of CD40 in human B cell differentiation, J. Immunol., 150, 1276
9. Aruffo, A., Farrington, M., Hollenbaugh, D., Li, X., Milatovich, A., Nonoyama, S., Bajorath, J., Grosmaire, L. S., Stenkamp, R , Neubauer, M., Roberts, R. L , Nicolle, R. J., Ledbetter, J. A., Francke, U. and Ochs, H. D. (1993). The CD40 ligand, gp39, is defective in activated T cells from patients with X-linked hyper-IgM syndrome, Cell, 72, 291.
10. Cutler, R C., Armitage, R. J., Conley, M. E., Rosenblatt, H. Jenkins, N. A., Copeland, N. G., Bedell, M. A., Edelhoff, S., Disteche, C. M., Simoneaux, D. K., Fanslow, W. C., Belmont, J. and Spriggs, M. K. (1993). CD40 ligand gene defects responsible for X-linked hyper IgM syndrome. Science, 259, 990.
11. Foy, T M., Shephard, D M., Durie, F. H., Aruffo, A., Ledbetter, J. A. and Noelle, R. J. (1993) In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. II. Prolonged supression of the humoral immune response by an antibody to the ligand for CD40, gp39, J. Exp. Med., 178, 1567.
12. Ashwell, J. D., Longo, D. L. and Bridges, S. H. (1987). T-cell tumor elimination as a result of T-cell receptor-mediated activation. Science, 237, 61.
13. Beckwith, M., Longo, D. L , O'Connell, C. D., Moratz, C. M. and Urba, W. J. (1990). Phorbol ester-induced, cell-cycle-specific, growth inhibition of human B-lymphoma cell lines, J. Natl Cancer Inst., 82, 501.
14. Beckwith, M., Urba, W. J., Ferris, D K., Freter, C. E. Kuhns, D. B., Moratz, C. M. and Longo, D. L. (1991). Anti-IgM-mediated growth inhibition of a human B lymphoma cell line is independent of phosphatidylinositol turnover and protein kinase C activation and involves tyrosine phosphorylation. J. Immunol., 147, 2411.
15. Bridges, S H., Kruisbeek, A. M. and Longo, D. L (1987). Selective in vivo antitumor effects of monoclonal anti-I-A antibody on B cell lymphoma, J. Immunol , 139, 4242.
16. Page, D. M. and Defranco, A. (1988). Role of phosphoinositide-derived second messengers in mediated anti-IgM-induced growth arrest of WEHI-231 B lymphoma cells, J. Immunol., 140, 3717.
17. Ghetie, M A., Picker, L. J., Richardson, J. A., Tucker, K., Uhr, J. W. and Vitetta, E. S. (1994). Anti-CD19 inhibits the growth of human B-cell tumor lines in vitro and of Daudi cells in SCID mice by inducing cell cycle arrest, Blood, 83, 1329.
18. Gruss, H J., Boiani, N., Williams, D. E., Armitage, R. J., Smith, C. A. and Goodwin, R. G. (1994). Pleiotropic effects of the CD30 ligand on CD30-expressing cells and lymphoma cell line, Blood, 83, 2045.
19. Funakoshi, F., Longo, D. L., Beckwith, M , Conley, D. K., Tsarfaty, G., Tsarfaty, I., Armitage, R. J., Fanslow, W. C., Spriggs, M. K. and Murphy, W. J (1994). Inhibition of human B-cell lymphoma growth by CD40 stimulation. Blood, 83, 2787.
20. Holder, M. J., Wang, H., Milner, A. E., Casamayor, M., Armitage, R., Spriggs, M. K., Fanslow, W. C., MacLennan, I. C. M., Gregory, C D. and Gordon, J. (1993). Suppression of apoptosis in normal and neoplastic human B lymphocytes by CD40 ligand is independent of Bcl-2 induction, Eur. J. Immunol., 23, 2368.
21. Johnson, P. W., Watt, S. M., Betts, D. R., Davies, D., Jordan, S., Norton, A. J. and Lister, T. A. (1993). Isolated follicular lymphoma cells are resistant to apoptosis and can be grown in vitro in the CD40/stromal cell system, Blood, 82, 1848.
22. Kawata, A., Yoshida, M., Okazaki, M., Yokota, S., Barcos, M. and Seon, B. K. (1994). Establishment of new SCID and nude mouse models of human B leukemia/lymphoma and effective therapy of the tumors with immunotoxin and monoclonal antibody: marked difference between the SCID and nude models in the antitumor efficacy of monoclonal antibody, Cancer Res , 54, 2688.
23. Funakoshi, S., Longo, D. L. and Murphy, W. J. (1996). Differential in vitro and in vivo antitumor effects mediated by anti-CD40 and anti-CD20 monoclonal antibodies against human B-cell lymphomas, J. Immunotherapy, 19, 93
24. Nakamine, H., Masth, A. S., Okano, M., Taguchi, Y., Pirruccello, S. J., Davis, J. R., Mahlock, M. L., Beisel, K. W., (Cleveland, K , Sanger, W. G. and Purtilo, D. T (1993). Characterization of clonality of Epstein-Barr virus-induced human B lymphoproliferative disease in mice with severe combined immunodeficiency, Am. J. Pathol., 142, 139.
25. Rowe, M., Young, L. S., Crocker, J., Stokes, H., Henderson, S. and Rickinson, A. B. (1991). Epstein-Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: implications for the pathogenesis of EBV-positive lymphomas in man, J. Exp. Med., 173, 147.
26. Murphy, W J., Bennett, M., Anver, M. R., Baseler, M. and Longo, D. L. (1992). Human-mouse lymphoid chimeras: host- vs -graft and graft-vs.-host reactions, Eur. J. Immunol., 22, 1421.
27. Murphy, W J., Durum, S. K., Anver, M., Frazier, M. and Longo, D. L. (1992). Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein- Barr virus-induced B-cell lymphoma. Brain Behav. Immun., 6, 355.
28. Funakoshi, S., Beckwith, M., Fanslow, W. C., Longo, D. L. and Murphy, W. J. (1995). Epstein Barr-virus induced human B- cell lymphomas arising in huPBL-SCID chimeric mice: characterization and the role of CD40 stimulation in their treatr and prevention. Pathobiology, 63, 133.
29. Nigro, J. M., Baker, S. J., Prisinger, A. C., Jessup, J M., Hostetter, R , Cleary, K., Binger, S. H., Davidson, N., Baylin, S. and Devilee, P. (1989). Mutatons in the p53 gene occur in diverse human tumor types, Nature, 342, 5.
30. Bartek, J., Bartkova, J., Vojtesek, B., Staskova, Z., Lukas, J., Rejthar, A., Kovarik, J., Midgley, C. A., Gannon, J. V. and Lane, D. P. (1991). Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies, Oncogene, 6, 1699.
31. Mosialos, G , Birkenbach, M. and Yalamanchili, R. (1995) The EBV transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family, Cell, 80, 389.
32. Ruby, J., Bluethmann, H , Aguet, M. and Ramshaw, I. A. (1995). CD40 ligand has potent antiviral activity, Nature Medicine, 1, 437.